Search
EuroSIDA Publications 2020

1 Uptake and discontinuation of integrase inhibitors (INSTIs) in a large cohort setting. L Greenberg, L Ryom,  G Wandeler, K Grabmeier-Pfistershammer, A Öllinger, B Neesgaard, C Stephan, A Calmy, A Rauch, A Castagna, V Spagnuolo, M Johnson, C Stingone, C Mussini, S De Wit, C Necsoi, AA Campins, C Pradier, M Stecher, J-C Wasmuth, A d’Arminio Monforte, M Law, R Puhr, N Chkhartishvili, T Tsertsvadze, H Garges, D Thorpe, JD Lundgren, L Peters, L Bansi-Matharu, and A Mocroft for the RESPOND study
J Acquir Immune Defic Syndr. 2020;83(3):240-250. Abstract

2 Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment
Mocroft A, Lundgren J, Gerstoft J, Rasmussen LD, Bhagani S, Aho I, Pradier C, Bogner JR, Mussini C, Uberti Foppa C, Maltez F, Laguno M, Wandeler G, Falconer K, Trofimova T, Borodulina E, Jevtovic D, Bakowska E, Kase K, Kyselyova G, Haubrich R, Rockstroh JK, Peters L; EuroSIDA Study.
Clin Infect Dis. 2020;70(10):2131-2140. Abstract

3 Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment. Mocroft, A, and RESPOND study group.
HIV Med. 2020 Abstract

Total publications May 2020: 297


IN PRESS
Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons 
Amanda Mocroft
L Ryom, C Oprea, Q Li, A Rauch, C Boesecke, V Uzdaviniene, D Sedlacek, JM. Llibre, K Lacombe,  LN. Nielsen,  Florence, I Aho, N Chkhartishvili, J Szlavik, G Dragovic, C Leen, H Sambatakou, T Staub, M Laguno, H Elinav, J Tomazic, L Peters, for the EuroSIDA study group
AIDS 2020 [Ahead of print]